At Cellestial Health we are pioneering a groundbreaking approach to brain health by targeting astrocytes, the vital brain cells that regulate multiple brain functions including movement, memory, and sleep, but have been overlooked by existing therapies.
While traditional therapies focus primarily on brain cells called neurons, novel research, including our study conducted at the
University of Cambridge, reveals that astrocytic networks are equally crucial for maintaining normal brain signalling.
In diseases like Parkinson’s, these networks become disrupted which can contribute to symptom development.
By protecting and stabilising astrocytes, we are offering a disruptive therapeutic strategy that addresses the underlying mechanisms of brain disorders, rather than masking symptoms.
Our primary mission is to stop Parkinson’s disease progression at the point of diagnosis using our innovative, brain-penetrant small molecule therapeutics designed to stabilise astrocytic networks. Unlike existing treatments that only temporarily reduce symptoms, our approach targets the root cause of multiple molecular hallmarks that drive disease progression, offering the potential for true disease modification.
With over 10 million people worldwide living with Parkinson’s, and approximately 150,000 in the UK alone, the need for disease-modifying therapies has never been more urgent. As Parkinson’s mainly affects individuals over the age of 60, the global incidence is set to rise dramatically with an ageing population, intensifying the need for groundbreaking therapeutic solutions.
Our unique approach targets astrocytic network biology, which becomes disrupted in many neurological diseases. This disruption provides the foundation for our Cellestial pipeline, a constellation of therapies, each designed to address different molecular targets within astrocytic networks.
With astrocytes playing a crucial role in maintaining brain health, this strategy opens the door to addressing a vast, unmet medical need, positioning Cellestial Health to tap into a market of wider CNS therapeutics valued at over $100 billion.
“By initially focusing on a single molecular pathway and specific disease area of Parkinson’s, Cellestial is maximizing the therapeutic impact while advancing efficiently and effectively through development stages. Look for Cellestial to bring the next big advancement in the treatment of Parkinson’s to the medical world giving those with this disease hope for their futures.”
Mr Stephen Grant, Chairman
“At Cellestial Health, we are pioneering next generation medicines with broad therapeutic applications in brain health and healthy brain ageing.“
Dr Nat Hastings, Chief Executive Officer